- Home
- JILL vs AKBA Comparison
JILL vs AKBA Comparison
Compare JILL & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JILL
- AKBA
- Stock Information
- Founded
- JILL 1959
- AKBA 2007
- Country
- JILL United States
- AKBA United States
- Employees
- JILL N/A
- AKBA N/A
- Industry
- JILL Clothing/Shoe/Accessory Stores
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- JILL Consumer Discretionary
- AKBA Health Care
- Exchange
- JILL Nasdaq
- AKBA Nasdaq
- Market Cap
- JILL 342.2M
- AKBA 336.2M
- IPO Year
- JILL 2017
- AKBA 2014
- Fundamental
- Price
- JILL $21.52
- AKBA $1.90
- Analyst Decision
- JILL Strong Buy
- AKBA Strong Buy
- Analyst Count
- JILL 6
- AKBA 1
- Target Price
- JILL $38.17
- AKBA $7.50
- AVG Volume (30 Days)
- JILL 83.2K
- AKBA 2.1M
- Earning Date
- JILL 03-19-2025
- AKBA 03-13-2025
- Dividend Yield
- JILL 0.98%
- AKBA N/A
- EPS Growth
- JILL 24.73
- AKBA N/A
- EPS
- JILL 2.82
- AKBA N/A
- Revenue
- JILL $614,918,000.00
- AKBA $169,879,000.00
- Revenue This Year
- JILL $2.96
- AKBA N/A
- Revenue Next Year
- JILL $3.03
- AKBA $19.31
- P/E Ratio
- JILL $7.64
- AKBA N/A
- Revenue Growth
- JILL 1.57
- AKBA N/A
- 52 Week Low
- JILL $20.81
- AKBA $0.80
- 52 Week High
- JILL $40.61
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- JILL 26.08
- AKBA 45.35
- Support Level
- JILL $20.93
- AKBA $1.72
- Resistance Level
- JILL $21.90
- AKBA $1.88
- Average True Range (ATR)
- JILL 1.04
- AKBA 0.09
- MACD
- JILL -0.28
- AKBA -0.00
- Stochastic Oscillator
- JILL 13.69
- AKBA 42.86
About JILL J. Jill Inc.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.